Abstract
This randomized, double-blind study comparing orchiectomy plus placebo to orchiectomy plus a nonsteroid antiandrogen (Anandron) shows that total androgen blockade for metastatic cancer of the prostate provides a significantly better early objective response when compared to castration alone. This response, however, is less apparent at 18 months. The study also suggests a longer survival for the patients with total androgen blockade.
Publication types
-
Clinical Trial
-
Comparative Study
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Androgen Antagonists / administration & dosage
-
Androgen Antagonists / therapeutic use*
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Buserelin / administration & dosage
-
Combined Modality Therapy
-
Double-Blind Method
-
Humans
-
Imidazoles / administration & dosage
-
Imidazoles / therapeutic use*
-
Imidazolidines*
-
Male
-
Neoplasm Metastasis
-
Neoplasms, Hormone-Dependent / drug therapy
-
Neoplasms, Hormone-Dependent / surgery
-
Orchiectomy*
-
Placebos
-
Prognosis
-
Prostatic Neoplasms / drug therapy
-
Prostatic Neoplasms / surgery*
-
Random Allocation
-
Remission Induction
Substances
-
Androgen Antagonists
-
Imidazoles
-
Imidazolidines
-
Placebos
-
nilutamide
-
Buserelin